MedPath

Mindfulness-based Stress Reduction for Multiple Sclerosis

Not Applicable
Completed
Conditions
Multiple Sclerosis
Registration Number
NCT02340754
Lead Sponsor
National University of Natural Medicine
Brief Summary

The primary purpose of this study is to assess the feasibility of mindfulness-based stress reduction (MBSR) for adults with any type of multiple sclerosis. The secondary objectives are to: 1) Explore the ability of MBSR to improve perceived stress and quality of life compared to an education control group; and 2) Explore the durability of the effects of MBSR over one year.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
67
Inclusion Criteria
  • Men and women 18 years of age or older
  • Definite relapsing remitting, secondary progressive, or primary progressive MS by revised McDonald criteria;
  • Expanded Disability Severity Scale ≤ 8 at baseline;
  • Stable on MS disease modifying, anxiolytic, or antidepressant medications for three months prior to baseline visit;
  • Mild to moderate stress defined by a score of ≥ 10 on the Perceived Stress Scale at screening;
  • Ability to read and write in English;
  • Willingness to provide informed consent and comply with study activities, including weekly MBSR sessions and daily practice or weekly Education Control classes.
Exclusion Criteria
  • MBSR or cognitive behavioral therapy training within the last 5 years;
  • Current regular meditation or yoga practice (weekly or more often);
  • MS exacerbation within 30 days of Baseline Visit;
  • Mini-Mental Status Examination (MMSE) score of ≤ 26 at Screening Visit;
  • Active suicidal ideation (Beck Depression Inventory) at Screening Visit;
  • Reported or medically recorded diagnoses of current serious psychological disorders other than depression and anxiety;
  • Other current life-threatening or severely disabling physical disorders;
  • Positive pregnancy urine test at Baseline and women planning pregnancy during the study period (contraception not required);
  • Cancer, other than basal or squamous skin cancers; or
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Recruitment: Number of participants enrolled over a ten-month periodRecruitment will be tracked monthly with an expected recruitment period of 10 months..

Feasible recruitment is defined as the ability to recruit and enroll 60 participants with multiple sclerosis (MS) over a ten-month time frame. Recruitment rate will be calculated as the proportion of eligible patients who provided informed consent per month.

Adherence to Mindfulness-based Stress Reduction (MBSR): Number of Participants who are present for at least 5 of the classes, including the final class, and complete at least 70% of homework.Baseline to 8 weeks

Adherence will be tracked with a sign-in/sign out sheet at each class and with daily homework logs. Attendance will be calculated by a sign in/sign out sheet, being present for at least 75% of a class will count as attended. Homework will be tabulated as both a frequency count (number of days homework was completed) and amount (total number of minutes completed). Participants who are present for at least 5 of the classes, including the final class, and complete at least 70% of homework will be recorded as 'adherent'.

Adoption: Qualitative assessment of facilitators of and barriers to participation in the MBSR program.Week 4 and week 8 of the 8 week intervention.

Adoption is defined as the ability of participants to take part in activities such as yoga poses and meditative exercises. Qualitative outcomes include a brief, semi-structured focus group conducted at the beginning of the MBSR classes during weeks five and eight. Focus groups will address successes and any challenges participants may be experiencing. Focus groups will be audio recorded and transcribed verbatim for qualitative analysis.

Completion: Number of participants with complete follow-up at 12 months post-intervention.14 months

A feasible completion rate is defined as complete follow-up in at least 70% of enrolled subjects at 12-months post-intervention. Completion indicates acceptability of a long-term trial and will inform future study designs.

Secondary Outcome Measures
NameTimeMethod
Change from baseline in Perceived Stress Scale at 8 weeksBaseline and 8 weeks
Change in Perceived Stress Scale from 8 weeks to 12 months8 weeks and 12 months
Change from baseline in Short Form-36 Mental Health Subscale to 8 weeksBaseline and 8 weeks

Mental health-related quality of life.

Change in Short Form-36 Mental Health Subscale from 8 weeks to 12 months8 weeks and 12 months

Mental health-related quality of life.

Change in baseline Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Score to 8 weeksBaseline and 8 weeks

PROMIS Computerized Adaptive Test of Anxiety

Change in PROMIS Anxiety Score from 8 weeks to 12 months8 weeks and 12 months

PROMIS Computerized Adaptive Test of Anxiety

Change in baseline PROMIS Depression Score to 8 weeksBaseline and 8 weeks

PROMIS Computerized Adaptive Test of Depression

Change in PROMIS Depression Score from 8 weeks to 12 months8 weeks and 12 months

PROMIS Computerized Adaptive Test of Depression

Change in baseline PROMIS Fatigue Score to 8 weeksBaseline and 8 weeks

PROMIS Computerized Adaptive Test of Fatigue

Change in PROMIS Fatigue Score from 8 weeks to 12 months8 weeks and 12 months

PROMIS Computerized Adaptive Test of Fatigue

Change in baseline PROMIS Pain Score to 8 weeksBaseline and 8 weeks

PROMIS Computerized Adaptive Test of Pain

Change in PROMIS Pain Score from 8 weeks to 12 months8 weeks and 12 months

PROMIS Computerized Adaptive Test of Pain

Trial Locations

Locations (1)

National College of Natural Medicine

🇺🇸

Portland, Oregon, United States

National College of Natural Medicine
🇺🇸Portland, Oregon, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.